Adam Miller

Managing Partner

Eric Rosenkranz

Partner

Lisa Strovink

Managing Partner

7 past transactions

Amulet

Series A in 2024
Amulet specializes in detecting invisible threats within the global food system. It offers two core brands: Allergy Amulet, a consumer product that alerts users to potentially life-threatening allergens in foods, and Amulet Scientific, which equips businesses with tools to ensure food supply chain safety.

ATANIS

Venture Round in 2023
ATANIS Biotech is a biotechnology company focused on advancing clinical allergy research and developing diagnostic assays. The company aims to enhance and simplify the standard of care for allergy diagnosis through its innovative functional cell-based assay. This novel approach not only streamlines the allergy diagnosis process but also predicts the effectiveness of various treatment options. By providing a reliable tool for functional allergy screening, ATANIS Biotech seeks to improve patient outcomes and support healthcare providers in managing allergy-related conditions more effectively.

IgGenix

Series B in 2023
IgGenix, Inc. is a biotechnology company focused on developing an innovative antibody therapeutics platform aimed at treating food and non-food allergies, as well as other severe allergic conditions. The company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies, which are designed to alleviate and potentially prevent allergic reactions. By capturing and analyzing rare human B cells that express allergen-binding antibodies, IgGenix engineers these antibodies to incorporate immune-modulating activities derived from the IgG class, thereby enhancing their ability to suppress allergic responses. Founded in 2019 and based in South San Francisco, California, IgGenix is dedicated to addressing the challenges posed by life-threatening allergic reactions through its advanced therapeutic solutions.

Alladapt Immunotherapeutics

Venture Round in 2022
Alladapt Immunotherapeutics is a privately held biopharmaceutical company focused on developing prescription therapeutics for food allergy. Based in Menlo Park, California, it was founded in 2018. The company’s lead program, ADP101, is a broad-spectrum oral immunotherapy designed to mitigate, treat, and prevent reactions to foods by targeting single or multiple allergen proteins across common allergens.

IgGenix

Series A in 2021
IgGenix, Inc. is a biotechnology company focused on developing an innovative antibody therapeutics platform aimed at treating food and non-food allergies, as well as other severe allergic conditions. The company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies, which are designed to alleviate and potentially prevent allergic reactions. By capturing and analyzing rare human B cells that express allergen-binding antibodies, IgGenix engineers these antibodies to incorporate immune-modulating activities derived from the IgG class, thereby enhancing their ability to suppress allergic responses. Founded in 2019 and based in South San Francisco, California, IgGenix is dedicated to addressing the challenges posed by life-threatening allergic reactions through its advanced therapeutic solutions.

Bryn Pharma

Venture Round in 2021
Bryn Pharma LLC is a biotechnology company based in Raleigh, North Carolina, that specializes in the research and development of an innovative bi-dose intranasal device designed for the administration of epinephrine in emergency situations related to anaphylaxis. This needle-free nasal solution serves as an alternative to traditional epinephrine auto-injectors, offering a portable and easy-to-use option for patients. The device is designed to be simple enough for individuals without any medical training to operate, making it accessible for those at risk of severe allergic reactions. Established in 2017 and previously known as Epi-Now, LLC, Bryn Pharma aims to enhance the treatment experience for patients facing allergic emergencies.

Allergy Amulet

Seed Round in 2020
Allergy Amulet Inc. is a Madison, Wisconsin-based company that specializes in the manufacture and sale of consumer food allergen sensors. Founded in 2016, the company has developed the Allergy Amulet, which is recognized as the world's smallest and fastest sensor for detecting common allergenic ingredients in food. This innovative device caters to a wide audience, including families, individuals, children, and businesses, allowing users to test food for allergens in seconds. Its sleek and portable design enables users to carry it conveniently on a keychain, necklace, or wristband, promoting safety and peace of mind for those affected by food allergies. With food allergies impacting approximately 32 million Americans and hundreds of millions globally, Allergy Amulet aims to enhance the quality of life for individuals with food allergies or intolerances.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.